1 not yet recruiting, 1 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Terminated 1 |
Follow SCLC, Recurrent: new trials by email Literature Review of SCLC, Recurrent trials Research Report on SCLC, Recurrent
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC Paclitaxel Polymeric Micelles, Ivonescimab - SCLC, Recurrent | Phase 2 | Not yet recruiting | Shaodong Hong | 47 | 2026-10-01 | 2026-09-15 |
| AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer Durvalumab+AZD2811 to SCLC patients - SCLC, Recurrent | Phase 2 | Terminated | Se-Hoon Lee | 4 | 2020-09-18 | 2022-02-25 |
Recurrence (2) · Small Cell Lung Carcinoma (1)
Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
Se-Hoon Lee (1) · Shaodong Hong (1)
China (1) · South Korea (1)